

AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

Claims 1-21. (Canceled)

22. (Currently Amended) A method for treating leukemia, comprising selecting a patient in need thereof and administering to the patient an effective amount of a humanized anti-human VEGF receptor Flt-1 antibody which has destroys leukemia cells through antibody-dependent cellular cytotoxic activity against leukemia cells equal to or greater than that of the humanized VEGF Flt-1 antibody generated by YB2/3HL.P2.G11.16Ag.20 cells.

Claim 23. (Canceled)

24. (Currently Amended) The method according to claim 22, wherein the humanized anti-human VEGF receptor Flt-1 antibody is an antibody comprising complementarity determining regions of an antibody selected from the group consisting of antibody KM1730 produced by hybridoma KM1730 (FERM BP-5967), antibody KM1731 produced by hybridoma KM1731 (FERM BP-5718), antibody KM1732 produced by hybridoma KM1732 (FERM BP-5698), antibody KM1748 produced by hybridoma KM1748 (FERM BP-5699) and antibody KM1750 produced by hybridoma KM1750 (FER[[N]]M BP-5700).

Claims 25. (Canceled)

26. (Currently Amended) The method according to claim 22, wherein the humanized anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of ~~Fab, Fab', F(ab')₂~~, a single chain antibody and a disulfide stabilized antibody.

27. (Previously Presented) The method according to claim 22, wherein the humanized anti-human VEGF receptor Flt-1 antibody is an antibody fused with a radioisotope or a protein or a low molecular weight anticancer agent by a chemical or genetic engineering means.

Claim 28. (Canceled)

29. (Currently Amended) ~~[[A]]~~The method according to claim 22~~for treating leukemia, comprising selecting a patient in need thereof and administering to the patient an effective amount of~~ wherein the humanized anti-human VEGF receptor Flt-1 antibody is a human chimeric anti-human VEGF receptor Flt-1 antibody which destroys leukemia cells through antibody dependent cellular cytotoxic activity.

30. (Previously Presented) The method according to claim 29, wherein the human chimeric anti-human VEGF receptor Flt-1 antibody is an antibody which belongs to the IgG type.

31. (Previously Presented) The method according to claim 29, wherein the human chimeric anti-human VEGF receptor Flt-1 antibody is an antibody which belongs to the IgG1 type.

32. (Currently Amended) The method according to claim 29, wherein the human chimeric anti-human VEGF receptor Flt-1 antibody is an antibody comprising a variable region heavy chain and a variable region light chain of an antibody selected from the group consisting of antibody KM1730 produced by hybridoma KM1730 (FERM BP-5967), antibody KM1731 produced by hybridoma KM1731 (FERM BP-5718), antibody KM1732 produced by hybridoma KM1732 (FERM BP-5698), antibody KM1748 produced by hybridoma KM1748 (FERM BP-5699) and antibody KM1750 produced by hybridoma KM1750 (FER[[N]]M BP-5700).